Triple-negative breast cancer (TNBC) represents the most aggressive subtype of BC, characterized by the absence of estrogen receptors, progesterone receptors, and the human epidermal growth factor receptor-2 (HER2), which are usually targeted in therapy for the more common BC subtypes [3,4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.